Identifying high-risk triple-negative breast cancer patients by molecular subtyping
Breast Care — Hartung C, Porsch M, Stückrath K, et al. | October 21, 2021
The clinical relevance of molecular subtyping of triple-negative breast cancer [TNBC; the most aggressive type of breast cancer (BC)] in improving the individual indication of systemic therapy has been investigated.
From a prospective, multicenter cohort including 1,270 histopathologically confirmed invasive, non-metastatic BCs, researchers obtained 124 (82%) of 152 TNBC tumors and performed molecular subtyping on them.
PAM50 analysis led to identification of 87% of the tumors as basal with an inferior clinical outcome compared with patients with nonbasal tumors.
Twenty-three (15%) of TNBCs were identified as luminal androgen receptor (LAR) subtype using the TNBCtype-6 classifier.
Patients with LAR subtype can be identified via performing molecular analysis and subtyping of TNBC.
Given the less sensitivity of patients with LAR subtype to conventional chemotherapy, exploration of new treatment options, including androgen receptor-blocking agents and immune checkpoint inhibitors, is stressed.
Read the full article on Breast Care